(Q43952848)

28 November 2017

Immune responses to Plasmodium falciparum antigens during a malaria vaccine trial in Tanzanian children (English)

1 reference

28 November 2017

0 references

Plasmodium falciparum

0 references

0 references

1 reference

14

1 reference

28 November 2017

16

Tanner M

1 reference

28 November 2017

0 references

Alonso PL

1

1 reference

28 November 2017

Lopez MC

2

1 reference

28 November 2017

Bordmann G

3

1 reference

28 November 2017

Smith TA

4

1 reference

28 November 2017

Aponte JJ

5

1 reference

28 November 2017

Weiss NA

6

1 reference

28 November 2017

Urassa H

7

1 reference

28 November 2017

Armstrong-Schellenberg JR

8

1 reference

28 November 2017

Kitua AY

9

1 reference

28 November 2017

Masanja H

10

1 reference

28 November 2017

Thomas MC

11

1 reference

28 November 2017

Oettli A

12

1 reference

28 November 2017

Hurt N

13

1 reference

28 November 2017

Kilama WL

15

1 reference

28 November 2017

1 February 1998

1 reference

28 November 2017

1 reference

28 November 2017

20

1 reference

28 November 2017

2

1 reference

28 November 2017

63-71

1 reference

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum

28 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Gamma-globulin and acquired immunity to human malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Efficacy trial of malaria vaccine SPf66 in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Some effects of partial malaria suppression in Ugandan children during the first 3 years of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3024.1998.00125.X

10.1046/J.1365-3024.1998.00125.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference